-
Notifications
You must be signed in to change notification settings - Fork 0
Expand file tree
/
Copy pathentrepreneurship.html
More file actions
454 lines (439 loc) · 24.3 KB
/
entrepreneurship.html
File metadata and controls
454 lines (439 loc) · 24.3 KB
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
<!DOCTYPE html>
<html>
<head>
<style>
/* hides "Team:Cornell" and iGEM logo */
#top_title {
display: none;
}
/* removes padding below footer */
#globalWrapper {
padding: 0;
}
#content {
padding: 0px;
width: 100% !important;
margin-top: 0px;
margin-left: 0px;
}
/* removes default styling for home banner tagline */
#HQ_page p {
font-family: 'Open San', sans-serif;
font-size: 16px;
font-weight: 100;
color: #000;
padding-top: 0;
padding-bottom: 0;
}
/* removes small extra margin at very bottom below footer */
p {
margin: 0;
}
/* removes bullets from Toolkit dropdown menu */
ul {
list-style-image: none;
}
</style>
<title>Team:Cornell - 2020.igem.org</title>
<!-- CSS -->
<link rel="stylesheet" type="text/css" href="styles/styles.css">
<link rel="stylesheet" type="text/css" href="styles/grids.css">
<link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.5.2/css/bootstrap.min.css" integrity="sha384-JcKb8q3iqJ61gNV9KGb8thSsNjpSL0n8PARn9HuZOnIxN0hoP+VmmDGMN5t9UJ0Z" crossorigin="anonymous">
<!-- JS -->
<script src="https://code.jquery.com/jquery-3.5.0.js"></script>
<script>
$(document).ready(function() {
$('.standard-page-side-bar-wrapper').css({
'position': 'fixed',
'display': 'none'
});
$('body').scroll(function() {
/* Check the location of each desired element */
$('.standard-page-side-bar-content-wrapper').each(function(i) {
var top_of_object = $(this).position().top;
var top_of_window = $(window).scrollTop();
/* If the object is completely visible in the window, fade it it */
if ((top_of_window > top_of_object)) {
console.log("HELLO");
$('.standard-page-side-bar-wrapper').css({
'position': 'fixed',
'display': 'block'
});
}
if ((top_of_window < top_of_object)) {
$('.standard-page-side-bar-wrapper').css({
'position': 'fixed',
'display': 'none'
});
}
});
});
});
</script>
</head>
<!--NOTE: REMEMBER TO CHANCE active-page CLASS TO CORRECT DROPDOWN-->
<body>
<div class="standard-page-wrapper">
<!------------------------ NAV BAR START ------------------------>
<nav>
<div class="nav-bar-wrapper">
<div class="nav-bar-main-menu">
<a href="index.html"><img class="nav-bar-logo" src="images/cornell-igem-logo-white.png" alt="logo"></img>
<div class="dropdown">
<button class="dropbtn">TEAM</button>
<div class="dropdown-content team-dropdown-content">
<a href="bios.html">BIOS</a>
<a href="sponsors.html">SPONSORS</a>
<a href="attributions.html">ATTRIBUTIONS</a>
</div>
</div>
<div class="dropdown">
<button class="dropbtn">OUTREACH</button>
<div class="dropdown-content outreach-dropdown-content">
<a href="education.html">EDUCATION & ENGAGEMENT</a>
<a href="collabs.html">COLLABORATIONS</a>
</div>
</div>
<div class="dropdown">
<button class="dropbtn active-nav">HUMAN PRACTICES</button>
<div class="dropdown-content human-dropdown-content">
<a href="practicesfinal.html">INTEGRATED PRACTICES</a>
<a href="policies.html">POLICIES</a>
<a href="entrepreneurship.html">ENTREPRENEURSHIP</a>
</div>
</div>
<div class="dropdown">
<button class="dropbtn">PRODUCT DEVELOPMENT</button>
<div class="dropdown-content human-dropdown-content">
<a href="modeling.html">MODELING</a>
<a href="engineeringsuccess.html">ENGINEERING SUCCESS</a>
<a href="hardware.html">HARDWARE</a>
<a href="implementation.html">IMPLEMENTATION</a>
</div>
</div>
<div class="dropdown">
<button class="dropbtn">TOOLKIT</button>
<div class="dropdown-content toolkit-dropdown-content">
<ul>
<div class="nav-first-col">
<li class="wet-lab-list-title"><b>WET LAB</b></li>
<li><a href="foundation.html">FOUNDATIONS</a></li>
<li><a href="demonstrate.html">DEMONSTRATE</a></li>
<li><a href="part.html">PARTS</a></li>
<li><a href="basic_part.html">BASIC PARTS</a></li>
<li><a href="composite_parts.html">COMPOSITE PARTS</a></li>
</div>
<div class="nav-second-col">
<li class="pd-list-title"><b>DOCUMENTATION</b></li>
<li><a href="notebook.html">NOTEBOOK</a></li>
<li><a href="safety.html">SAFETY</a></li>
<li><a href="contribution.html">CONTRIBUTION</a></li>
</div>
</ul>
</div>
</div>
<div class="dropdown">
<button class="dropbtn" onclick="location.href='description.html'">DESCRIPTION</button>
</div>
<div class="dropdown">
<button class="dropbtn" onclick="location.href='index.html'">HOME</button>
</div>
</div>
</div>
</nav>
<!------------------------ NAV BAR END ------------------------->
<!------------------------ STANDARD PAGE BANNER START ------------------------>
<header class="standard-page-banner">
<img class="standard-page-banner" src="images/banners/entrepreneuership.png" alt="entrepreneurship banner">
</header>
<!------------------------ STANDARD PAGE BANNER END ------------------------>
<!------------------------ STANDARD PAGE SIDE BAR + CONTENT START ------------------------>
<div class="standard-page-side-bar-content-wrapper">
<!------------------------ STANDARD PAGE SIDE BAR START ------------------------>
<div class="standard-page-side-bar-wrapper">
<ul class="standard-page-side-bar">
<li><a href="#pageheading1">Overview</a></li>
<li><a href="#pageheading2">Market Analysis (SWOT)</a></li>
<li><a href="#pageheading3">Product Comparison and<br>Comparative Statistics</a></li>
<li><a href="#pageheading4">Future of Lumicure</a></li>
</ul>
</div>
<!------------------------ STANDARD PAGE SIDE BAR END ------------------------>
<!------------------------ STANDARD PAGE CONTENT START ------------------------>
<div class="standard-page-content-wrapper">
<div class="standard-page-content-section">
<div class="standard-page-content-title">
<div id="pageheading1">Overview</div>
</div>
<hr class="yellow-accent-line-left">
<br>
<br>
<p class="standard-page-content-text">
In today’s healthcare world, cancer treatment remains tied to traditional, expensive, and debilitating methods of chemotherapy and radiation. Oftentimes, patients are monitored at infrequent rates and treated aggressively and with little
attention to impact on other facets of health. Some patients are unable to progress with treatment because of the overwhelming side effects and others cannot afford the care; still others find treatments to be futile in the face of their
rapidly worsening conditions. Many recovered patients undergo the physically and financially draining treatment process, only to find that their cancers had returned to significant extents years later when a relapse could have been
stopped if detection was earlier and more routine. Alternative methods such as immunotherapy are incredibly steep in price, remaining available only to the affluent.
<br>
<br>
In making Lumicure, the Cornell iGEM team wanted to create a product that attempts to tackle all of the barriers and dilemmas cancer patients face today, from treatment cost to efficacy to screening frequency. Lumicure’s components,
Trichoscan and Trichotherapy, represent revolutionary diagnostic and cancer therapeutic protocols that harness the power of the novel field of bacteriotherapy to produce an affordable, reliable and effective cancer therapy supplement that
may eventually become a primary form of treatment in the near future. Lumicure is a project that is rooted in a dream for more progressive cancer treatment and driven by a trust and acknowledgement of how synbio can help achieve it.
</p>
</div>
<div class="standard-page-content-section">
<div class="standard-page-content-title">
<div id="pageheading2">Market Analysis (SWOT)</div>
</div>
<hr class="yellow-accent-line-left">
<br>
<div class="standard-page-content-subheading">Strengths</div>
<p class="standard-page-content-text">
Lumicure is a low toxicity, high-specificity treatment for targets that are most deleterious to fast-growing cancer cells. Our system employs a prolonged treatment effect, rather than a single-time drug delivery mechanism. This means that
the patient will only incur the one-time cost of implementing the system, rather than individual, expensive doses.
<br><br>
Because of its adaptive nature, bacteriotherapy also treats and tracks metastatic cancer more effectively than current therapies. Although metastases are not always detected through a CT scan, they can still be treated by Lumicure because
the bacteria can settle into smaller tumors and produce the therapeutic protein Trichosanthin as well as the mCardinal signaling molecule. Our treatment also uses a sophisticated, non-invasive method to detect the E. coli in the body
through fluorescence detection.
</p>
<div class="standard-page-content-subheading">Weaknesses</div>
<p class="standard-page-content-text">
Universal acceptance of bacteria as a treatment medium stands as a barrier to the use of our system. Despite recent advances in the field, bacteriotherapy remains a novel and experimental form of treatment. Much more research and testing
must be performed on a clinical level before bacteriotherapy can be considered as a safe and viable standalone alternative; as such, Lumicure currently remains a supplementary treatment system.
<br><br>
Bacteriotherapy treatments also currently face some limitations in their applicability. Effective usage of Lumicure requires the tumor to be significant in size before the treatment can be employed. Additionally, the treatment may be
limited to a small range of cancers with a certain genetic composition and/or location in the body.
</p>
<div class="standard-page-content-subheading">Opportunities</div>
<p class="standard-page-content-text">
Lumicure’s bacteriotherapy treatment is a viable alternative to late stage treatment drugs, most of which have significant levels of toxicity, and many detrimental side effects. Because of the cell-specific action of Lumicure bacteria
(hypoxic tumor sites) and the low toxicity of the drug Trichosanthin to non-cancer cells, Lumicure and future bacteriotherapy systems represent a risk-free future for cancer treatment.
<br><br>
The population of patients in need of cancer treatment is ever-growing, and the cost of cancer therapeutics is constantly increasing as well. With its low frequency administration model, Lumicure may be able to outpace other forms of
cancer treatment by saving on expenses and increasing accessibility. There is also the possibility of expanding Lumicure to treat other types of cancers, such as colon cancer, brain cancer, and liver cancer.
</p>
<div class="standard-page-content-subheading">Threats</div>
<p class="standard-page-content-text">
In order to emerge on the current market of cancer therapeutic systems, Lumicure and its associated components will have to be approved by the FDA and go through an extensive patenting process. This process typically takes 8-10 years, and
involves multiple phases that require sequential approval through vigorous examination. After approval, additional measures need to be taken to approve Lumicure as a government-backed subsidized treatment rather than as a privatized
company brand (which will result in the treatment cost being too high for most patients).
<br><br>
Furthermore, improving tumor detection mechanisms throughout the industry have also curbed the need for mixed diagnostic-delivery systems like those employed by Lumicure’s Trichotherapy/Trichoscan combination. There is a possibility that
such a system may be financially unviable due to additional unforeseen costs in developing complementary services such as ways of administering the bacteria and imaging devices.
</p>
</div>
<div class="standard-page-content-section">
<div class="standard-page-content-title">
<div id="pageheading3">Product Comparison and Comparative Statistics</div>
</div>
<hr class="yellow-accent-line-left">
<br>
<br>
<table border="0" style="width: 100%;">
<tr valign="top">
<td>
<table border="1">
<caption>Trichoscan Imaging System (per unit)</caption>
<tr>
<th>Material</th>
<th>Price ($)</th>
</tr>
<tr>
<td>Dichroic Mirror/filter block</td>
<td>300</td>
</tr>
<tr>
<td>Light source (lasers)</td>
<td>50</td>
</tr>
<tr>
<td>Raspberry pi unit</td>
<td>30</td>
</tr>
<tr>
<td>Raspberry pi camera</td>
<td>30</td>
</tr>
<tr>
<td>Total</td>
<td><u>$410</u></td>
</tr>
</table>
</td>
<td>
<table border="1">
<caption>Lumicure Preparation (per treatment)</caption>
<tr>
<th>Material</th>
<th>Price ($)</th>
<th>Unit</th>
</tr>
<tr>
<td>Labor</td>
<td>300 (approx.)</td>
<td>10 hours</td>
</tr>
<tr>
<td>E. Coli</td>
<td>153</td>
<td>1.2 mL</td>
</tr>
<tr>
<td>NEB Golden Gate Assembly</td>
<td>150</td>
<td>20 rxns</td>
</tr>
<tr>
<td>Lambda Red Cloning</td>
<td>20</td>
<td>1 unit</td>
</tr>
<tr>
<td>Total</td>
<td><u>233.75</u></td>
<td>--</td>
</tr>
</table>
</td>
</tr>
<tr valign="top">
<td>
<table border="1">
<caption>Common Breast Cancer Diagnostic Methods</caption>
<tr>
<th>Methods</th>
<th>Average Price</th>
<th>Source/ Notes</th>
</tr>
<tr>
<td>3D Mammogram</td>
<td>$231</td>
<td><a
href="https://www.mdsave.com/procedures/3d-mammogram-screening-tomosynthesis/d784fbc5#:~:text=How%20Much%20Does%20a%203D%20Mammogram%20Screening%20(Tomosynthesis)%20Cost%3F,shop%2C%20compare%20prices%20and%20save.">MDSave</a>
Per instance</td>
</tr>
<tr>
<td>Caris Molecular Intelligence (CMI)</td>
<td>£995 $1,164</td>
<td><a href="https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-019-0191-6">BMC</a> Per person per cycle</td>
</tr>
<tr>
<td>Breast MRI with Contrast</td>
<td>$525</td>
<td> <a href="https://www.mdsave.com/t/imaging-radiology/how-much-does-mri-cost">MDSave</a> Per instance</td>
</tr>
<tr>
<td>Ultrasound Breast Unilateral</td>
<td>$185</td>
<td> <a href="https://www.mdsave.com/procedures/ultrasound-breast-unilateral-1-breast/d785f9c9">MDSave</a> Per instance </td>
</tr>
<tr>
<td>Breast Biopsy</td>
<td>$2,423</td>
<td><a href="https://www.mdsave.com/procedures/breast-biopsy/d78af5cf#:~:text=On%20MDsave%2C%20the%20cost%20of,shop%2C%20compare%20prices%20and%20save.">MDSave</a></td>
</tr>
<tr>
<td>Lumicure</td>
<td>$410</td>
<td>Price per use for 50 uses ~$8</td>
</tr>
</table>
</td>
<td>
<table border="1">
<caption>Breast Cancer Average Treatment Costs</caption>
<tr>
<th>Stage</th>
<th>Total Cost of Treatment (2 Years)</th>
<th>Cost per Day</th>
</tr>
<tr>
<td>0</td>
<td>$71,909</td>
<td>$98.51</td>
</tr>
<tr>
<td>I/II</td>
<td>$97,066</td>
<td>$132.97</td>
</tr>
<tr>
<td>III</td>
<td>$159,442</td>
<td>$218.41</td>
</tr>
<tr>
<td>IV</td>
<td>$182,655</td>
<td>$250.21</td>
</tr>
<tr>
<td>(Trichotherapy+Trichoscan)=Lumicure Supplement</td>
<td>$643.75</td>
<td>$0.88</td>
</tr>
</table>
</td>
</tr>
</table>
<br>
<p class="standard-page-content-text">
In a study comparing the treatment costs for breast cancer, it was found that average costs allowed per patient in the 24 months after the index diagnosis were $71,909, $97,066, $159,442, and $182,655 for disease stage 0, I/II, III, and
IV, respectively. As a supplement, Lumicure represents less than 1% of the total yearly cost of treatment at each of the stages for 1 usage and personal scanning unit.
</p>
</div>
<div class="standard-page-content-section">
<div class="standard-page-content-title">
<div id="pageheading4">Future of Lumicure</div>
</div>
<hr class="yellow-accent-line-left">
<div class="standard-page-content-subheading">Product Developement</div>
<p class="standard-page-content-text">
Cornell University facilitates licensing of research produced by students and CU iGEM will likely pursue patents for the components of the Lumicare system for future collaboration and expansion. For example, a patent could be pursued for
the engineered bacteria as well as the Trichoscan hardware system built to enhance cancer detection. Filing for such patents would be performed through the Cornell Center for Technology Licensing (CTL).
<br><br>
In terms of the product life cycle, Lumicure is still in the first stage of development. A foreseeable course of action for post-competition product would be as follows:
<br>
<ol>
<li><b>Patent approval</b>: secure patents for the engineered bacteria and PD system through the FDA. This process, which involves non-human experimentation, clinical trials and pre-approval measures, will span 8-10 years.</li>
<li>
<b>Introduction phase</b>: heavy investments into advertising and a promotion campaign will help introduce the public to the concept of bacteriotherapy. This awareness movement will center around how treatment is administered and its benefits when compared to other breast cancer treatments.
<br>
At this stage, the customer base would consist of innovators and early adopters, as bacteriotherapy is a very new treatment that has yet to be widely accepted in the medical field.
</li>
<li>
<b>Growth</b>: is expected to occur after raising public awareness, successfully treating patients and developing enough funding and backing to distribute Lumicure on a national level. Reflected by growing demand, increases in production, and expansion of availability. Lumicure would become widely accepted as a viable alternative to more commonplace breast cancer treatments like surgery and chemotherapy.
</li>
</ol>
</p>
<div class="standard-page-content-subheading">Goals</div>
<p class="standard-page-content-text">
Given that Lumicure is a theoretical demonstration of a therapeutic avenue for cancer treatment, CU iGEM will likely implement a partnership growth strategy in the short term, whereby our team can provide information and expertise to companies looking to develop similar products. This is a low risk, low reward growth tactic, but has great potential to facilitate a commercial product based on Lumicure’s prototype. Before the lengthy patenting process for Lumicure itself can be completed, our collaboration with other like-minded organizations can plant the seeds for the standardization of cancer bacteriotherapy treatment in the future.
<br><br>
The ultimate goal of CU iGEM’s Lumicure project is to come up with a bacteriotherapy treatment that is as affordable and as accessible of a product as possible. Therefore, realizing our long term goal involves patent approval with the FDA and negotiations with governments and healthcare organizations to subsidize the market-ready design. CU iGEM’s objective is for Lumicure to provide a cheaper and more valuable method of cancer treatment than current solutions, whether it remains as an auxiliary treatment or becomes a primary one.
</p>
</div>
</div>
<!------------------------ STANDARD PAGE CONTENT END ------------------------>
</div>
<!------------------------ STANDARD PAGE SIDE BAR + CONTENT END ------------------------>
<!------------------------ FOOTER START ------------------------>
<footer>
<div class="footer-wrapper">
<div class="icon-wrapper">
<a class="icon" href="http://facebook.com/cornelligem"><img src="https://2019.igem.org/wiki/images/4/44/T--Cornell--Facebook.png"></a>
</div>
<div class="icon-wrapper">
<a class="icon" href="http://twitter.com/cugem"><img src="https://2019.igem.org/wiki/images/8/80/T--Cornell--Twitter.png"></a>
</div>
<div class="icon-wrapper">
<a class="icon" href="https://www.instagram.com/cugem/"><img src="https://2019.igem.org/wiki/images/3/37/T--Cornell--Instagram.png"></a>
</div>
<div class="icon-wrapper icon-wrapper-last">
<a class="icon" href="https://www.youtube.com/channel/UCJt-5JfyoucUJXC1EsTllhg"><img src="https://2019.igem.org/wiki/images/3/3c/T--Cornell--Youtube.png"></a>
</div>
</div>
</footer>
<!------------------------ FOOTER END ------------------------>
</div>
</body>
</html>